Adverse events and hematopoietic recovery
| . | −G-CSF . | +G-CSF . | P . |
|---|---|---|---|
| Adverse events grade 3 or 4, % | |||
| Cycle 1 | |||
| Side effects, % | 52 | 55 | .18 |
| Infections, % | 88 | 92 | .14 |
| Cycle 2 | |||
| Side effects, % | 63 | 64 | .91 |
| Infections, % | 90 | 92 | .70 |
| Hematopoietic recovery, d (median) | |||
| Cycle 1 | |||
| ANC > 0.5 × 109/L | 29 | 29 | .70 |
| Platelets > 50 × 109/L | 27 | 27 | .56 |
| Cycle 2 | |||
| ANC > 0.5 × 109/L | 28 | 31 | .007 |
| Platelets > 50 × 109/L | 35 | 40 | .02 |
| . | −G-CSF . | +G-CSF . | P . |
|---|---|---|---|
| Adverse events grade 3 or 4, % | |||
| Cycle 1 | |||
| Side effects, % | 52 | 55 | .18 |
| Infections, % | 88 | 92 | .14 |
| Cycle 2 | |||
| Side effects, % | 63 | 64 | .91 |
| Infections, % | 90 | 92 | .70 |
| Hematopoietic recovery, d (median) | |||
| Cycle 1 | |||
| ANC > 0.5 × 109/L | 29 | 29 | .70 |
| Platelets > 50 × 109/L | 27 | 27 | .56 |
| Cycle 2 | |||
| ANC > 0.5 × 109/L | 28 | 31 | .007 |
| Platelets > 50 × 109/L | 35 | 40 | .02 |
The criteria of the World Health Organization were used to categorize adverse effects. The percentages of patients with any grade 3 or 4 side effect or infection are given. Side effects do not include hair loss. Infections do not include fever of unknown origin. The time to hematopoietic recovery was measured from the start of chemotherapy.